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. Introduction
The foundation of immunology is based on self-nonself discrim-
nation [1]. Most of the pathogens contain molecular signatures
hat can be recognized by the host and trigger immune responses
2]. Unlike pathogens, these molecular signatures are not gen-
rally expressed by tumor cells, making them more difﬁcult to
e distinguished from normal cells. However, T cells can recog-
ize tumor antigens expressed by tumor cells. A class of tumor
ntigens, named tumor-associated antigens, is expressed in some
ormal tissues at low levels but is over-expressed in malignant
ells. Many of the tumor-associated antigens have been identi-
ed as the targets of tumor-reactive T cells, isolated from tumor
nﬁltrating lymphocytes (TILs), from draining lymph nodes or from
eripheral blood [3]. However, expression of these antigens in nor-
al  cells can trigger central and peripheral tolerance mechanisms
hat lead to the selection of T cells with low-afﬁnity T cell receptors
TCR). Conversely, attempts to target tumor-associated antigens
ith high-afﬁnity TCRs can lead to severe toxicities due to normal
issue destruction [4,5].
Another class of tumor antigens is tumor-speciﬁc neoantigens,hich arise via mutations that alter amino acid coding sequences
non-synonymous somatic mutations). Some of these mutated pep-
ides can be expressed, processed and presented on the cell surface,
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044-5323/Published by Elsevier Ltd This is an open access article under the CC BY-NC-Nand subsequently recognized by T cells. Because normal tissues
do not possess these somatic mutations, neoantigen-speciﬁc T
cells are not subject to central and peripheral tolerance, and also
lack the ability to induce normal tissue destruction. As a result,
neoantigens appear to represent ideal targets for T cell-based can-
cer immunotherapy.
2. Approaches to identify T cell neoantigens
2.1. Classical approaches
Some of the initial attempts were focused on common shared
mutations that have been well-characterized. Short peptides were
synthesized based on the sequences of mutated BRAF [6,7], KRAS
[8–11] and p53 [12]. T cells from patients’ or healthy donors’
blood were stimulated several times by peptide-pulsed target cells,
and expanded T cells were studied for their ability to kill tumors
carrying these mutations. Alternatively, cells with overexpressed
mutated cDNA, such as mutated NRAS cDNA, could serve as target
cells to detect and isolate neoantigen-reactive T cells [13].
However, the majority of the neoantigen-reactive T cells rec-
ognized unique mutations not shared between cancer patients.
Most of the unique neoantigens were identiﬁed by cDNA library
screening in the past two decades. In this approach, cDNA library
and MHC  molecules were over-expressed in cell lines, and then
co-cultured with T cells to identify antigens that could induce the
T cell activation, measured by cytokine secretion or 4-1BB up-
regulation. Table 1 is the list of published neoantigens identiﬁed
by this approach.
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table  1
Human neoantigens discovered by classical approaches.
Cancer type Year Mutated gene name Approach Source of T cells Reference
Melanoma 1995 CDK4 cDNA library PBL [14]
Melanoma 1995 MUM1  cDNA library PBL [57]
Melanoma 1996 CTNNB1 cDNA library TIL [15]
Melanoma 1999 CDC27 cDNA library TIL [58]
Melanoma 1999 TRAPPC1 cDNA library PBL [59]
Melanoma 1999 TPI Chromatographic puriﬁcation TIL [60]
Melanoma 2000 ASCC3 cDNA library PBL [61]
Melanoma 2001 HHAT cDNA library TIL [62]
Melanoma 2002 FN1 cDNA library TIL [63]
Melanoma 2002 OS-9 cDNA library PBL [64]
Melanoma 2003 PTPRK cDNA library TIL [65]
Melanoma 2004 CDKN2A**, HLA-A11 cDNA library TIL [18]
Melanoma 2005 GAS7, GAPDH cDNA library TIL [66]
Melanoma 2005 SIRT2, GPNMB, SNRP116, RBAF600, SNRPD1 cDNA library PBL [67]
Melanoma 2005 Prdx5 cDNA library PBL [68]
Melanoma 2011 CLPP cDNA library TIL [69]
Melanoma 2013 PPP1R3B cDNA library TIL [46]
Lung cancer 1998 EF2 Chromatographic puriﬁcation PBL [20]
Lung cancer 2001 ACTN4 cDNA library TIL [70]
Lung cancer 2001 ME1  cDNA library PBL [71]
Lung Cancer 2006 NF-YC cDNA library draining lymph node [72]
Renal cancer 1996 HLA-A2 cDNA library PBL [17]
Renal cancer 1999 HSP70-2 cDNA library TIL [73]
Renal cancer 2005 KIAA1440 cDNA library PBL [74]
HNSCC 1997 CASP8 cDNA library PBL [16]
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CIL: tumor inﬁltrating lymphocytes; PBL: peripheral blood lymphocytes; HNSCC: H
** Frame-shift mutation.
Neoantigens have been identiﬁed predominantly in melanoma,
ikely due to the relatively high mutation rate in this tumor
ype. Nonetheless, neoepitopes have also been identiﬁed in mul-
iple tumor types including lung and renal cancers. The majority
f neoantigens were encoded by point-mutated gene products,
lthough frameshift deletion and insertions have also been found
o generate neoepitopes. Some mutated gene products recognized
y T cells appear to be driver mutation products and play a role
n tumorigenesis. These include CDK4, -catenin (CTNNB1) and
aspase-8 (CASP8) proteins [14–16]. Interestingly, HLA-A2 and A11
ontaining point-mutations have also been identiﬁed as tumor-
peciﬁc T cell antigens, suggesting that somatic mutations in HLA
olecules can be a source of neoantigens [17–19].
In another approach, a mutated (EF2) and non-mutated
gp100:154) T cell epitopes have been identiﬁed by using mass
pectrometry to sequence peptides that were eluted from HLA
olecules isolated from the surface of tumor cells [20]. This
pproach has been limited by the sensitivity of these methods.
evertheless, recent advances in the sensitivity and throughput of
hese techniques may  facilitate the application of this approach to
dentifying tumor antigens.
.2. Approaches utilizing next-generation sequencing techniques
Although the classical cDNA library screening approach led
o the discovery of multiple neoantigens, this approach is
abor-intensive and low-throughput. In addition, some large
ranscripts, GC-rich transcripts and low-expression transcripts
annot be cloned easily, leading to the failure of identifying
ome mutated antigens. Recently, several investigators have taken
dvantage of whole-exome sequencing technologies to identify
on-synonymous mutations in tumors. These mutated genes were
ubjected to in silico analysis to predict potential high-afﬁnity
pitopes that bind to MHC  molecules [21–23]. Additional ﬁlters
ould be applied to eliminate (1) epitopes predicted to be poorly
rocessed by the immunoproteasome and (2) epitopes with lower
inding afﬁnity than the corresponding wild-type sequences [24].
andidate mutated peptides were synthesized and screened tod neck squamous cell carcinoma.
identify T cell neoantigens. This approach could be very efﬁ-
cient, and could identify neoantigens where previous cDNA library
screening failed to discover [25].
This peptide-based screening approach, while effective in iden-
tifying many epitopes, may  nevertheless be limited by the accuracy
of MHC/HLA-binding prediction algorithms, which have not been
thoroughly examined for MHC  class II alleles and infrequent HLA
alleles. In addition, the expression of potential T cell epitopes on
the cell surface is inﬂuenced by a variety of mechanisms, espe-
cially the expression of multiple forms of the proteasome, which
limit the number of peptides that are truly processed and presented
[26,27]. An alternative approach is pulsing antigen presenting cells
with relatively long synthetic peptides that encompass minimal
T cell epitopes [28]. In a recent report, nonsynonymous mutated
epitopes were identiﬁed in three melanoma lesions by evaluat-
ing the response of CD4+ TIL to autologous B cells that were
pulsed with 31 amino-acid long peptides encompassing individ-
ual mutations. Use of this approach resulted in the identiﬁcation
of mutated CIRH1A, GART, ASAP1, RND3, TNIK, RPS12, ZC3H18 and
LEMD2 T cell epitopes. Furthermore, in a recent report, a peptide
screening was carried out based on the combination of two  peptide
libraries: (1) 15-mer overlapping long-peptides (2) peptides based
on MHC-binding prediction. This screening led to the identiﬁcation
of mutated HSDL1-reactive T cells isolated from an ovarian tumor
[29].
To solve all the potential issues mentioned above, we  have
developed a tandem minigene screening approach [30]. A tandem
minigene construct comprised 6 to 24 minigenes that encoded
polypeptides containing a mutated amino acid residue ﬂanked on
their N- and C-termini by 12 amino acids. Tandem minigene con-
structs were synthesized and used to transfect autologous APCs
or cell lines co-expressing autologous HLA molecules. Using this
approach, mutated KIF2 C and POLA2 epitopes were identiﬁed in
two melanoma patients [30]. In addition, a mutated ERBB2IP epi-
tope was  identiﬁed in a patient with cholangiocarcinoma [31].
Recent studies using this approach have led to the identiﬁcation
of mutated antigens express on gastrointestinal, breast and ovar-
ian cancers [32] (and unpublished data). Notably, the neoantigen
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eactivity could be identiﬁed from TILs isolated from patients with
holangiocarcinoma or gastrointestinal cancer, which has a rela-
ively low number of mutations.
A recent approach combined whole-exome/transcriptome
equencing analysis, MHC  binding prediction, as well as mass spec-
rometric technique to detect peptides eluted from HLA molecules
33]. Interestingly, only a small fraction of predicted high-binding
eptides were conﬁrmed by mass spectrometry. The relative small
umber of mutated peptides identiﬁed by mass spectrometry
ight be due to the sensitivity of the peptide puriﬁcation and mass
pectrometry, but it could also suggest that natural antigen process
nd presentation in cells could be very inefﬁcient. Among 7 neo-
pitopes identiﬁed by this approach, mutated Adpgk, Reps1 and
pagt1 epitopes were conﬁrmed to be immunogenic [33].
. The correlation between neoantigens and tumor
egressions
It has been established that T cells recognizing non-mutated
umor antigens could induce tumor regression [34]. This has been
emonstrated by clinical trials involving adoptive transfer of T cells
argeting HLA-A*0201-restricted NY-ESO-1. Objective responses
ere observed in 61% of patients with synovial cell sarcoma, 55%
f patients with melanoma and 80% of patients with myeloma
35–37]. However, it remains unclear whether T cells recognizing
eoantigens can also induce tumor regression in human.
In the past few years, there have been signiﬁcant advances in
heckpoint blockade cancer immunotherapy. Tumor regressions
ere observed in a portion of cancer patients who underwent CTLA-
, PD-1 or PD-L1 blockade clinical trials [38]. Currently, the widely
cceptable hypothesis is that tumors with more mutations likely
enerate more neoepitopes, which can be recognized by tumor
nﬁltrating T cells. Checkpoint blocking antibodies reactivate these
 cells in vivo and induce tumor regressions. As a result, cancers with
igh mutation rates, such as melanoma and lung cancer, are more
usceptible to checkpoint blockade therapies. (One notable excep-
ion for this hypothesis is renal cell carcinoma, which is susceptible
o checkpoint blockade therapies but with low mutation load). A
ecent study in a murine model has provided some evidence for this
ypothesis. In an anti-PD-1 and/or anti-CTLA-4 immunotherapy
odel, two dominant neoantigens asparagine-linked glycosylation
 (Alg8) and laminin alpha subunit 4 (Lama4) were identiﬁed from a
arcoma cell line d42m1-T3. Mutated Lama4 and Alg8 long peptide
accines could induce tumor rejection comparable to checkpoint
lockade immunotherapy. In addition, the checkpoint blockade
mmunotherapy increased the number and enhanced the activity of
eoantigen-speciﬁc CD8+ T cells [24]. These results suggested that
eoantigens and neoantigen-speciﬁc T cells were strongly associ-
ted with tumor regressions after checkpoint blockade therapy.
In human, recent studies have established the correlation
etween the number of mutations/neoantigens and clinical out-
omes. In a PD-1 blockade clinical trial comparing colorectal
ancer patients with or without mismatch-repair deﬁciency, pro-
onged progression-free survival was associated with high somatic
utations, which were found in tumors with mismatch repair-
eﬁciency [39]. Other studies utilized in silico analyses to predict
otential high-afﬁnity neoepitopes for calculating the numbers of
eoantigens. In two anti-CTLA-4 melanoma immunotherapy stud-
es, the number of neoantigens was signiﬁcantly associated with
linical beneﬁts after CTLA-4 blockade therapies [40,41]. How-
ver, it’s unclear whether the presence of “tetrapeptide” signatures
ithin predicted T cell epitopes could be employed to predict the
linical outcomes for the anti-CTLA-4 immunotherapy [40,41]. Sim-
lar to CTLA-4 blockade studies, higher neoantigen burden was
orrelated with clinical beneﬁt and progression-free survival inmmunology 28 (2016) 22–27
PD-1 blockade immunotherapy for patients with non-small cell
lung cancer [42]. These studies suggested that the number of
neoantigens was positively associated with clinical beneﬁt after
immune checkpoint blockade therapies. Lastly, adoptive transfer of
mixed TILs could induce tumor regressions in melanoma patients
[43]. In a recent study from our group, objective tumor regres-
sions in three melanoma patients were associated with adoptive
transferring of TILs, which all recognized neoantigens [25]. In a sub-
sequent study, two  TIL products were associated with complete
tumor regressions observed in two melanoma patients, and each
TIL could recognize one unique neoantigen [30]. Taken together,
these correlative studies suggested that neoantigen-reactive T cells
were likely the dominant player inducing tumor regressions in
patients.
4. Current evidence of cancer immunotherapy targeting
neoantigens
The ﬁrst approach to target neoantigens is via cancer vaccine.
In an initial mouse study, candidate mutated epitopes were identi-
ﬁed by whole-exome sequencing of the B16F10 murine melanoma.
Fifty selected mutation-coding long peptides were injected into
mice to elicit immune responses, and 11 out of 50 peptides induced
immune responses preferentially recognizing the mutated epi-
topes. Among these 11 peptides, mutated Kif18b (K739 N) was
found to be the dominant mutated antigens, and mice immu-
nized with mutated Kif18b peptide could slow tumor growth and
improve survival [22]. In another study, MC-38 tumor-bearing
mice vaccinated with mutated peptides (Adpgk, Reps1 and Dpagt1)
showed sustainable inhibition of tumor growth [33]. Recently, a
synthetic RNA “pentatope” vaccine was developed. Each pentatope
contained ﬁve 27-mer minigenes with the mutated amino acids
in the center, and each fused to each other by 10-mer glycine-
serine linker (pentatopes). The immunization of this RNA pentatope
conferred disease control and survival beneﬁt in a murine CT26
tumor model. Notably, mutated MHC  class II epitopes were more
immunogenic than class I epitopes in this study [44]. A recent
study has brought a neoantigen cancer vaccine to a clinical trial
in which whole-exome sequencing was carried out to identify
somatic mutations in tumors from 3 patients with melanoma.
Candidate HLA-A*02:01 epitopes containing residues arising from
mutations were initially ﬁltered using an HLA binding prediction
algorithm, and then evaluated using competitive binding assays.
Three patients were vaccinated with autologous dendritic cells that
had been pulsed with the top 7 highest binding peptides identiﬁed
from each tumor. The breadth and diversity of neoantigen-speciﬁc
T cells were increased in all 3 patients after the vaccination. In
addition, the results indicated that T cells generated by vaccina-
tion with 7 out of the 21 epitopes could recognize target cells
transfected with the corresponding tandem minigene constructs,
indicating that these neoantigens could be endogenously processed
and presented [45]. While these results demonstrated that neoanti-
gen cancer vaccines could elicit neoantigen-speciﬁc T cells in cancer
patients, no clinical beneﬁts to these patients were shown in this
study. It remains unclear whether current cancer vaccine thera-
pies are potent enough to provide therapeutic beneﬁts in cancer
patients with bulky disease.
The second approach to target neoantigens is by transfer-
ring neoantigen-speciﬁc T cells directly into host. Although so
far no evidence in mouse models has shown that such T cells
can induce tumor regressions in vivo, some evidence has linked
neoantigen-reactive T cells to tumor regressions in human. A
clue came from a report studying a unique melanoma TIL prod-
uct, without any reactivity against non-mutated antigens. Instead,
∼50% of this TIL product showed predominant reactivity against
Y.-C. Lu, P.F. Robbins / Seminars in Im
Table  2
Outstanding questions for cancer immunotherapy targeting neoantigens.
1. How does this approach overcome the heterogeneity of tumor?
2. Does the number of neoantigens correlate with the mutation rate in each
tumor specimen?
3. Can this approach apply to a variety types of cancers, especially cancers
with low mutation rate?
4. Can neoantigens induce tolerance? Can Treg speciﬁcally recognize
neoantigens and induce tolerance?
5. Are the number and ﬁtness of neoantigen-speciﬁc T cells important for
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[54–56] (and unpublished data). It is possible that patients with a
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vthe efﬁcacy of cancer immunotherapy?
LA-A*01-restricted mutated PPP1R3B. Following adoptive trans-
er of this TIL product, the patient experienced a complete
esponse ongoing beyond 10 years. In addition, mutated PPP1R3B-
eactive T cells could be still detected in the patient’s peripheral
lood 5 years after the immunotherapy [46]. The most direct
linical evidence came from an adoptive cell transfer immunother-
py using nearly pure neoantigen-reactive T cells. A patient
ith metastatic cholangiocarcinoma was treated with one billion
utated ERBB2IP-reactive CD4+ T cells, and she experienced a par-
ial response ongoing for more than 2 years since treatment [31].
his suggested that neoantigen-reactive T cells could induce long-
erm tumor regressions in cancer patients, and it also brought up
he possibility of applying immunotherapy to a variety of cancer
ypes other than melanoma.
. Conclusions and future perspectives
Based on current knowledge, neoantigens are ideal targets
or cancer immunotherapy. Because neoantigens are speciﬁcally
xpressed in the tumor, it is less likely to induce tolerance and
early impossible to induce normal tissue toxicity. However, it
emains challenging to reduce the cost of such highly personalized
herapy.
Many outstanding questions remain unanswered (Table 2). How
an we apply cancer immunotherapy to a variety of cancer types
y targeting neoantigens? Does the average number of neoanti-
ens discovered per tumor correlate with the mutation rate in each
ancer type? If yes, how can we apply immunotherapy to can-
ers with low mutation rates? Does the tumor microenvironments
n different cancer types inﬂuence the efﬁcacy of immunother-
py? Can the ﬁtness or the number of T cells overcome the
ig. 1. Cancer immunotherapy targeting neoantigens by the adoptive transfer of genetica
 cancer patient. Part of the tumor specimen will be subjected to whole-exome sequenc
sed  to grow TILs. Potential neoantigens will be identiﬁed by minigene or peptide screen
ntroduced into patient’s peripheral blood T cells. These genetically-modiﬁed T cells will
accine will be injected to enhance the strength and persistence of T cells.munology 28 (2016) 22–27 25
potentially harsh tumor microenvironment in different cancer
types?
One major concern is the heterogeneity of tumor. Neoantigens
may  be expressed in some tumor cells, but not all tumor cells in an
individual patient, leading to tumor escape from immunotherapy.
Conversely, we and others have observed complete tumor regres-
sions in dozens of patients after immunotherapy. Some potential
approaches may  address this concern. One is to target multiple
neoantigens at the same time, so all tumor cells expressing at least
one neoantigen can be destroyed. Another approach is to target
a single neoantigen, which is ideally expressed in all tumor cells
within a patient.
Targeting driver mutations can be an effective strategy [30].
Aggressive tumor cells are actively expressing driver mutations,
which are essential for carcinogenesis or metastasis. Although
some tumor cells may  not express driver mutations and may
escape from immunotherapy, those tumor cells likely lose the
metastatic potential and cannot grow aggressively. Nonetheless,
deﬁning driver mutations versus passenger mutations remains a
challenging issue. The most deﬁnitive way  to identify driver muta-
tions is based on the functional studies found in the literature.
From the neoantigens reviewed in this article, CDK4, -catenin and
Caspase-8 are likely driver mutations. The majority of neoantigens
are likely random mutations (passenger mutations) recognized by T
cells, but it is also possible that some of the mutations are simply not
well-characterized. The Cancer Genome Atlas attempted to address
this issue by sequencing and analyzing hundreds of tumor spec-
imens. The recurrent mutations were identiﬁed as the potential
driver mutations [47–49].
Recent checkpoint blockade immunotherapies have shown
some efﬁcacies in lung cancer, bladder cancer and renal can-
cer [50–53]. Based on the assumption that neoantigen-reactive T
cells are responsible for tumor regressions in checkpoint block-
ade immunotherapies, directly transferring neoantigen-reactive T
cells into cancer patients may  achieve a much higher response
rate. Additionally, neoantigen cancer vaccines may  enhance the
strength and persistence of T cells, and ultimately improve the
efﬁcacy of immunotherapy. With the recent advances in technol-
ogy, we can identify neoantigens and isolate neoantigen-speciﬁc
TCRs from individual patients in a timely and cost effective mannerwide variety of cancer types, including cancers with very few muta-
tions, can receive this proposed cancer immunotherapy targeting
neoantigens (Fig. 1).
lly-modiﬁed T cells. In this proposed study, a tumor will be surgically resected from
ing to identify nonsynonymous mutations. The rest of the tumor specimen will be
ing approach described in the text. Neoantigen-speciﬁc TCRs will be isolated and
 be adoptively transferred back to the patient to ﬁght cancer. A neoantigen cancer
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